<<<<<<< HEAD ======= >>>>>>> test

Supporting your patients as they take their next step with extended adjuvant therapy

Access and reimbursement support for NERLYNX

For patients prescribed with NERLYNX tablets, Puma Patient Lynx provides the following support services:

  • Benefits Verification and Prior Authorization Assistance
    Our reimbursement counselors will conduct a benefits investigation, verify insurance approval or coverage, and obtain and submit necessary documentation for patients requiring prior authorization.

  • Financial Support
    For patients with financial needs, we will work to find appropriate sources for support.

  • Co-Pay Assistance
    Puma Biotechnology offers co-pay assistance to help qualified insured patients with the out-of-pocket costs associated with their NERLYNX prescription.

  • NERLYNX Quick Start
    Provides a free 3-week supply of NERLYNX to eligible patients experiencing delays in gaining access to therapy.

Ongoing treatment support

For patients currently taking NERLYNX, Puma Patient Lynx provides the following services:

  • Product Support
    Our specialty pharmacy network will provide patients with product education and side-effect counseling to help them better understand and manage their NERLYNX therapy.

  • Text Message Support Program
    Patients can sign up to receive medication reminders and motivational messages to support treatment adherence.

For more information on the Puma Patient Lynx
Support Program:

1-855-816-5421,
Monday–Friday,
9 AM–8 PM ET

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.